Core Viewpoint - The law firm Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1]. Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's Vykat XR as overpriced and potentially unsafe for children, leading to a share price decline of $5.73, or approximately 7.41%, from $77.36 to $71.64 [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of Vykat XR due to adverse effects was around 8% at the end of Q3 2025. The CEO noted a disruption in the product's launch trajectory following the Scorpion Capital report, resulting in a further share price drop of $16.98, or approximately 26.59%, from $63.85 to $46.87 [4].

Core Viewpoint - Soleno Therapeutics, Inc. is under investigation for potential violations of federal securities laws following negative reports about its product Vykat XR, which has led to significant declines in its stock price [1][2]. Group 1: Company Performance - On August 15, 2025, a report by Scorpion Capital labeled Vykat XR as overpriced and potentially unsafe for children, resulting in a stock price drop of $5.73, or approximately 7.41%, from $77.36 to $71.64 [1]. - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in stock price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [2]. Group 2: Management Response - The CEO of Soleno acknowledged a disruption in the launch trajectory of Vykat XR following the negative report from Scorpion Capital, citing a decrease in start forms and an increase in discontinuations for non-serious adverse events [2].

Core Viewpoint - Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1] Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Vykat XR as overpriced and potentially unsafe for children, leading to a decline in Soleno's share price by $5.73, or approximately 7.41%, from $77.36 to $71.64 [3] - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [4]

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws or unlawful business practices [1] Group 1: Company Overview - Soleno Therapeutics, Inc. is under scrutiny following a report by Scorpion Capital that criticized its only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [2] - The company's stock price experienced significant declines following negative reports and disclosures about Vykat XR, with a drop of approximately 7.41% on August 15, 2025, and a further decline of about 26.59% on November 5, 2025 [2][3] Group 2: Financial Impact - Following the Scorpion Capital report, Soleno's share price fell from $77.36 to $71.64, a decrease of $5.73 per share [2] - On November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price from $63.85 to $46.87, a drop of $16.98 per share [3]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential violations of federal securities laws by Soleno Therapeutics, Inc. and its officers regarding misleading statements and undisclosed material information to investors [1][2]. Group 1: Investigation Details - The investigation focuses on whether Soleno's communications accurately represented the commercial progress and safety profile of VYKAT™ XR after its FDA approval [2]. - Following the FDA clearance in September 2025, Soleno claimed that the product rollout was exceeding internal expectations [2]. Group 2: Earnings Call Insights - During the third-quarter earnings call on November 4, 2025, Soleno acknowledged challenges in the launch of VYKAT™ XR, including a slowdown in new treatment initiations and an increase in therapy discontinuations due to non-serious adverse events [3]. - Management indicated that external commentary earlier in the year had negatively impacted the launch trajectory [3]. Group 3: Short Seller Report - On August 15, 2025, Scorpion Capital released a report raising concerns about VYKAT™ XR, questioning its safety profile, demand sustainability, and the concentration of early prescribing activity [4]. - The report criticized Soleno's business model for being overly reliant on a single product with impending intellectual property expiration and suggested that certain clinical research needed further examination [4]. Group 4: Stock Price Volatility - Following the Scorpion report, Soleno's stock price experienced significant volatility, declining nearly 40% from August 14, 2025, to November 5, 2025 [5].

Core Viewpoint - Soleno Therapeutics, Inc. experienced a significant drop in share price by $18.78 (-28%) following disappointing news regarding its drug VYKAT™ XR, which is intended to treat hyperphagia associated with Prader-Willi syndrome [1][2]. Company Performance - The company had previously assured investors of a successful launch of VYKAT™ XR after receiving FDA approval, stating that the launch "has been going really well" and "definitely exceeded our expectations" [2]. - However, during the Q3 2025 earnings call, Soleno disclosed a disruption in the launch trajectory, citing a lower number of start forms and increased discontinuations due to non-serious adverse events [2]. Market Reaction - Following the negative news, Soleno's share price fell nearly 40% from August 14, 2025, to November 5, 2025 [4]. - The market reaction was influenced by concerns raised by short seller Scorpion Capital, which highlighted potential risks associated with VYKAT™ XR, including reports of children hospitalized for heart failure after using the drug [3][4]. Investigations and Allegations - Hagens Berman, a national shareholders rights firm, is investigating whether Soleno misled investors regarding the commercial prospects of VYKAT™ XR [5]. - Scorpion Capital characterized Soleno as a "one-trick pony" with no other significant assets or pipeline, raising doubts about the company's future if VYKAT™ XR fails [3][4]. - Allegations were made regarding the integrity of clinical trial data and the influence of a controversial physician involved in key trials, suggesting potential irregularities in the company's disclosures [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The law firm is reaching out to investors who purchased or acquired Soleno shares and suffered losses, encouraging them to discuss their legal rights [1][2]. - There is no cost or obligation for investors to contact the firm regarding these claims [2]. Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3]. Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The law firm is reaching out to Soleno stockholders who have suffered losses, encouraging them to discuss their legal rights and options [1][2] - There is no cost or obligation for stockholders to inquire about their rights or the ongoing investigation [2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3] Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product Vykat XR, which led to a significant drop in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Soleno Therapeutics, Inc. and is looking into claims of securities fraud or other unlawful practices by the company and its officers [1]. - The investigation was prompted by a report from Scorpion Capital that criticized Soleno's only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [3]. Group 2: Stock Price Impact - Following the release of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, which is a decline of 7.41%, closing at $71.63 per share on the same day [3]. Group 3: Company Background - Soleno Therapeutics, Inc. is a company that has been under scrutiny due to concerns regarding its product and business practices, which may affect investor confidence and market performance [1][3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product, Vykat XR, which led to a significant drop in the company's stock price [1][2]. Group 1: Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO [1]. - The company's only product, Vykat XR, has been criticized as overpriced and potentially unsafe for children according to a report by Scorpion Capital [2]. Group 2: Stock Performance - Following the publication of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, representing a decline of 7.41%, closing at $71.63 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].